CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D012891: Sleep Apnea Syndromes NIH

(Synonyms: Sleep A, Sleep Ap, Sleep Apn, Sleep Apne, Sleep Apnea Sy, Sleep Apnea Syn, Sleep Apnea Synd, Sleep Apnea Syndr, Sleep Apnea Syndrom, Sleep Apnea Syndrome, Sleep Apnea Syndromes, Sleep Apnea,, Sleep Apnea,)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)


Name (Synonyms) Correlation
drug2644 Sleep Education Wiki 0.50
drug491 Buspirone + PAP therapy Wiki 0.50
drug515 CK0802 Wiki 0.50
drug3157 Zolpidem + PAP therapy Wiki 0.50
drug138 Acetazolamide + supplemental oxygen + PAP therapy Wiki 0.50
drug1260 Home Sleep Apnea Testing or In-hospital Polysomnography Wiki 0.50
drug502 CBT-OSA Wiki 0.50
drug2122 Placebo Wiki 0.03

Correlated MeSH Terms (8)


Name (Synonyms) Correlation
D020181 Sleep Apnea, Obstructive NIH 0.87
D020182 Sleep Apnea, Central NIH 0.50
D001049 Apnea NIH 0.50
D053120 Respiratory Aspiration NIH 0.16
D040921 Stress Disorders, Traumatic NIH 0.10
D013313 Stress Disorders, Post-Traumatic NIH 0.09
D013577 Syndrome NIH 0.05
D011014 Pneumonia NIH 0.03

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0010535 Sleep apnea HPO 1.00
HP:0002870 Obstructive sleep apnea HPO 0.87
HP:0002104 Apnea HPO 0.50
HP:0002871 Central apnea HPO 0.50
HP:0002090 Pneumonia HPO 0.03

There are 4 clinical trials

Clinical Trials


1 Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD

Approximately 20 million Americans suffer from Obstructive Sleep Apnea (OSA) creating risks for major health problems, including dementia, heart attack, and stroke. Obesity, a growing problem for Americans and Veterans alike, is the greatest risk factor for the development of OSA. Male gender and smoking, other OSA risk factors, are common in Veterans. Given the high comorbidity of these risk factors in Veterans, OSA presents a significant health burden to Veterans. The investigators' prior work provides evidence that OSA occurs in up to 69% of Vietnam-era Veterans with PTSD. OSA is easily treated; however, 15-30% of OSA patients are non-compliant with continuous positive airway pressure (CPAP), the standard OSA treatment. The proposed research aims to facilitate adherence to CPAP treatment by testing a novel cognitive-behavioral therapy intervention in Veterans with PTSD. If successful, it may represent an approach that could be applied to the rehabilitation of other chronic conditions with similar barriers to care.

NCT02641496 Obstructive Sleep Apnea PTSD Posttraumatic Stress Disorder Behavioral: CBT-OSA Behavioral: Sleep Education
MeSH:Sleep Apnea Syndromes Sleep Apnea, Obstructive Stress Disorders, Traumatic Stress Disorders, Post-Traumatic
HPO:Obstructive sleep apnea Sleep apnea

Primary Outcomes

Description: The CPAP machine will measure the number of hours that the CPAP mask is on the participant's face and in use.

Measure: Time in hours of "mask-on" CPAP usage per night

Time: 1 year

Secondary Outcomes

Description: Effect of CBT on Self-reported Everyday Activities, Mood and Quality of Life. The investigators hypothesize that after initiating CPAP treatment, Veterans in the CBT-OSA group will report more improvement in the ease of performing everyday activities compared to that reported by those in the Education group.

Measure: Functional Outcomes of Sleep Questionnaire (FOSQ)

Time: 1 year

Description: Effect of CBT on Cognitive Outcomes. The CBT-OSA group will have better cognitive outcomes than the Education group over time. The California Verbal Learning Test-II, Delayed Recall Score is the cognitive outcome measure.

Measure: California Verbal Learning Test, Second Edition (CVLT-II)

Time: 1 year

Description: Effect of CBT on PTSD. The CBT-OSA group will have fewer PTSD symptoms than the Education group over time. The PTSD Checklist for DSM-5 (PCL-5) will be the PTSD outcome measure.

Measure: PTSD Checklist for DSM-5 (PCL-5)

Time: 1 year

2 Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.

NCT04118387 Sleep Disordered Breathing Able Bodied Drug: Acetazolamide + supplemental oxygen + PAP therapy Drug: Zolpidem + PAP therapy Drug: Buspirone + PAP therapy
MeSH:Sleep Apnea Syndromes Respiratory Aspiration Sleep Apnea, Central
HPO:Central apnea Central sleep apnea Sleep apnea

Primary Outcomes

Description: CO2 reserve is the requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative.

Measure: CO2 reserve

Time: 120 days

Description: Central apnea indices is used to indicate the severity of central sleep apnea

Measure: Central apnea indices

Time: 120 days

Secondary Outcomes

Description: Controller gain is a ventilatory response to changes in end-tidal PCO2

Measure: Controller gain

Time: 120 days

Description: Plant gain is blood gas response to a change in ventilation. This measure represents the effectiveness of the "plant" in eliminating CO2.

Measure: Plant gain

Time: 120 days

Description: This measure represents the activity of the carotid bodies. It is measured by the decrease in ventilation in response to a single breath of 100% oxygen.

Measure: Carotid body function

Time: 120 days

Description: Peripheral chemoreflex sensitivity is measured either via brief hypoxia or a single breath of CO2.

Measure: Peripheral chemoreflex sensitivity

Time: 120 days

Description: The nadir pressure in the upper airway (supra-glottic pressure) prior to the occurrence of an arousal.

Measure: Respiratory arousal threshold

Time: 120 days

Description: To assess breathing stability, the investigators will measure % stable breathing using minute ventilation (VE) and tidal volume (VT) coefficient of variation as indices of breathing instability.

Measure: % stable breathing

Time: 120 days

3 Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study

Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.

NCT04363333 COVID Obstructive Sleep Apnea Pneumonia Diagnostic Test: Home Sleep Apnea Testing or In-hospital Polysomnography
MeSH:Apnea Sleep Apnea Syndromes Pneumonia Sleep Apnea, Obstructive
HPO:Apnea Obstructive sleep apnea Pneumonia Sleep apnea

Primary Outcomes

Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

Measure: The rate of clinical improvement

Time: 7 days

Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

Measure: The rate of clinical improvement

Time: 14 days

Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

Measure: The rate of clinical improvement

Time: 21 days

Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale

Measure: The rate of clinical improvement

Time: 28 days

Secondary Outcomes

Description: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality

Measure: Clinical status - improvement

Time: 7, 14, 21, 28 days

Description: Defined as an increase in category on a 7-category ordinal scale from admission

Measure: Clinical status - worsening

Time: 7, 14, 21, 28 days

Other Outcomes

Description: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.

Measure: Long-term outcomes

Time: 4-6 months after the initial hospital admission

4 Evaluation of Physical Activity Level and Sleep Quality in Patients With Obstructive Sleep Apnea Syndrome During Covid-19 Pandemic

As long as the people stay at home because of the Covid 19 outbreak, the investigators assume that the sleep quality of OUAS patients, like everyone else, and the sleep quality of COVID-19 outbreak are reduced due to anxiety and anxiety in people. In addition, we assume that sleep quality and physical activity level are related to health literacy level and fear of movement (kinesiophobia). In this study; the investigators aimed to determine how patients are affected by this process by evaluating sleep quality, physical activity, fear of movement and health literacy in OSAS patients during our stay in the COVID-19 outbreak.

NCT04451993 Obstructive Sleep Apnea-hypopnea Syndrome
MeSH:Sleep Apnea Syndromes Sleep Apnea, Obstructive Syndrome
HPO:Obstructive sleep apnea Sleep apnea

Primary Outcomes

Description: International Physical Activity Questionnaire/ In activity-specific scoring, walking under the heading of the fields is calculated by the sum of the moderate intensity activity and intensive activity in itself. From these calculations, a score is obtained in MET-minutes. There are 3 categories of physical activity level classification. Physical activity levels are classified as physically inactive (inactive), low level of physical activity (minimally active) and sufficient level of physical activity (very active)

Measure: Physical Activity

Time: 1 day

Description: The Pittsburgh Sleep Quality Index

Measure: Sleep Quality

Time: 1 day

Secondary Outcomes

Description: In order to measure the general sleepiness of people during the day, it was evaluated with a standard questionnaire, which is defined as Epworth sleepiness scale (EUS) and consists of 8 questions. The answers for each question are scored between 0 and 3 and the total score is obtained. The score obtained above 10 in EUS has high sensitivity and specificity for daytime sleepiness.

Measure: Daytime Sleepiness

Time: 1 day

Description: Tampa Kinesiophobia Scale (TKS)The person gets a total score between 17-68. The high score on the scale indicates that kinesiophobia is also high

Measure: Fear of movement

Time: 1 day

Description: Translated into Turkish TURKEY health literacy SCALE-32 (Tsoy-32) will be used. It was used to evaluate the literacy rates of individuals over the age of 15. 0 indicates the lowest health literacy and 50 indicates the highest health literacy.

Measure: Health literacy

Time: 1 day

Other Outcomes

Description: In the human circadian rhythm, the Morning Morning-Evening Survey (SAA) form was used, which determined morning and evening types.

Measure: Circadian rhythm evaluation

Time: 1 day


HPO Nodes